In a landmark development, the Pharmaceutical Society of Ghana (PSGH) successfully convened a crucial stakeholder meeting today to address the escalating tensions surrounding the Ministry of Health’s proposed decision to restrict certain medicines from importation for local manufacturing only. The meeting, facilitated by the PSGH president, Pharm. Dr. Samuel Kow Donkoh, brought together representatives from the Ghana National Chamber of Pharmacy (GNCoP), Pharmaceutical Importers and Wholesalers Association (PIWA) and the Pharmaceutical Manufacturers Association of Ghana (PMAG). PIWA was represented by their president Pharm. Dr. William Adum Addo, their Gen. Secretary, Pharm. Dr. Anthony Adjepong and their assistant  Secretary Pharm. Ronald Antwi. PMAG was represented by their president Pharm. Dr. Kofi Nsiah-Poku and their Executive Secretary, Pharm. Lucia Addae. On their side, the GNCoP was represented by their newly appointed first female CEO, Pharm. Audrey Serwaa Bonsu and Pharm. Dr. Kofi Addo-Agyekum.

Also present were Pharm. Dr. (Mrs.) Martha Gyansa-Lutterodt, a health policy expert and a former Director of the Technical Coordination Directorate of Ministry of Health, Pharm. Kwabena Offei Asante, Vice President of the PSGH, Rev. Dr. Dennis Senna Awitty, Executive Secretary, PSGH and Pharm. Dr. Harry Amoaning Okyere, Deputy Executive Secretary, PSGH.

Background

Previously, GNCoP and PIWA expressed concerns about the Ministry of Health’s proposed Executive Instrument restricting certain medicine imports, alleging a lack of transparency and potential negative consequences for public health. PMAG, advocating for the policy, disagreed with the position of PIWA and GNCoP, alleging that all required processes had been complied with, and therefore called for the swift implementation of the restriction policy.

The stakeholder meeting served as an effective platform for open dialogue and negotiation, leading to a significant breakthrough. Both parties agreed to a ceasefire in the media space and committed to finding a mutually acceptable solution. All parties agreed that there is the need to support local manufacturing in line with the PSGH strategic plan. Notable modifications to the proposed list were deliberated and aligned on. Regarding products listed on schedule four of the Executive Instrument, Stakeholders agreed to seek clarification from the Ministry of Health regarding the process for restricting medicines based on bioequivalence certification.

“We recognize the importance of collaboration for a sustainable solution that prioritizes public health and industry growth,” stated Dr. Addo-Agyekum of GNCoP. “This meeting marks a significant step towards achieving that.”

“We appreciate the opportunity to address concerns and work together on a fair and effective policy,” echoed Dr. Nsiah-Poku.

Dr. Gyansa-Lutterodt in her closing remarks praised the commitment to collaboration. “This meeting exemplifies the power of constructive dialogue in resolving differences,” She said. “By working together, we can ensure access to quality medicines for all Ghanaians.”

The President of the PSGH in his final remarks is quoted as saying, “I am profoundly encouraged by the spirit of compromise and collaboration demonstrated by all stakeholders at today’s historic meeting. Let us remember that the ultimate goal is not individual victory, but rather the creation of a robust and sustainable pharmaceutical ecosystem that prioritizes both access to quality medicines at affordable prices and the growth of a vibrant local manufacturing industry.”

This development signifies a positive step towards finding a balanced and inclusive resolution to the complex issues surrounding the proposed pharmaceutical importation restrictions. The stakeholders have demonstrated their commitment to working collaboratively in the best interest of public health and the pharmaceutical sector.

Stay tuned for further updates on this evolving story.